{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:42:44Z","timestamp":1780472564217,"version":"3.54.1"},"reference-count":89,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The aim of this review is to give an update on advances in evaluation and management of systemic sclerosis (SSc)-related Raynaud's phenomenon and digital ulceration, focusing on reports from the last 18 months. The increasing recognition of the huge impact of Raynaud's phenomenon and of digital ulceration on the everyday lives of patients with SSc has sparked enthusiasm internationally to develop better outcome measures and better treatments, and so a review is timely.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>There have been recent advances in the development of patient reported outcome instruments [e.g. the Hand Disability in Systemic Sclerosis-Digital Ulcers (HDISS-DU) instrument] and also in noninvasive imaging techniques, including thermography and laser Doppler methods. Improved outcome measures will facilitate future clinical trials, both early phase proof-of-concept and later phase trials. New insights have been gained into mechanisms of action and methods of administration of \u2018conventional\u2019 therapies, for example phosphodiesterase inhibitors and intravenous prostanoids. New treatment approaches are being investigated, including topical and procedural therapies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Clinicians can look forward to seeing these advances translating into clinical benefit over the next 5 years. To help ensure this, they should strive whenever possible to recruit patients with SSc-related digital vasculopathy into observational studies and clinical trials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000826","type":"journal-article","created":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T21:05:05Z","timestamp":1629666305000},"page":"453-462","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Raynaud's phenomenon and digital ulcers: advances in evaluation and management"],"prefix":"10.1097","volume":"33","author":[{"given":"Ariane L.","family":"Herrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41584-020-0386-4","article-title":"Raynaud phenomenon and digital ulcers in systemic sclerosis","volume":"16","author":"Hughes","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semarthrit.2016.02.005","article-title":"Impaired quality of life in systemic sclerosis and patient perception of the disease: a large international survey","volume":"46","author":"Frantz","year":"2016","journal-title":"Sem Arthritis Rheum"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00296-019-04436-z","article-title":"LAUDES Study: impact of digital ulcers on hand functional limitation, work productivity and daily activities, in systemic sclerosis patients","volume":"39","author":"Castellvi","year":"2019","journal-title":"Rheumatol Int"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/BOR.0000000000000332","article-title":"Recent advances in the pathogenesis and management of Raynaud's phenomenon and digital ulcers","volume":"28","author":"Herrick","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"e000826","DOI":"10.1136\/rmdopen-2018-000826","article-title":"Setting the international standard for longitudinal follow-up pf patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features","volume":"5","author":"Hoffman-Vold","year":"2019","journal-title":"RMD Open"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.10486","article-title":"Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon","volume":"46","author":"Merkel","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/2397198318774307","article-title":"Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report","volume":"3","author":"Pauling","year":"2018","journal-title":"J Scleroderma Rel Disorders"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/acr.21858","article-title":"Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials","volume":"65","author":"Galdue","year":"2013","journal-title":"Arthritis Care Res"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/art.40242","article-title":"Efficacy and safety of selexipag in adults with Raynaud's phenomenon secondary to systemic sclerosis: a randomized, placebo-controlled, Phase II Study","volume":"69","author":"Denton","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3899\/jrheum.180818","article-title":"Factors influencing Raynaud Condition Score diary outcomes in systemic sclerosis","volume":"46","author":"Pauling","year":"2019","journal-title":"J Rheumatol"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/rheumatology\/key026","article-title":"The patient experience of Raynaud's phenomenon in systemic sclerosis","volume":"58","author":"Pauling","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/acr.23475","article-title":"Multinational qualitative research study exploring the patient experience of Raynaud's phenomenon in systemic sclerosis","volume":"70","author":"Pauling","year":"2018","journal-title":"Arthritis Care Res"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/acr.23729","article-title":"Evolving symptom characteristics of Raynaud's phenomenon in systemic sclerosis and their association with physician and patient-reported assessments of disease severity","volume":"71","author":"Pauling","year":"2019","journal-title":"Arthritis Care Res"},{"issue":"(Suppl 3)","key":"R14-20250526","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.5152\/eurjrheum.2020.19124","article-title":"New perspectives in the imaging of Raynaud's phenomenon","volume":"7","author":"Herrick","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.semarthrit.2020.06.018","article-title":"Performance of laser-derived imaging for assessing digital perfusion in clinical trials of systemic sclerosis-related digital vasculopathy: a systematic literature review","volume":"50","author":"Pauling","year":"2020","journal-title":"Sem Arthritis Rheum"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.semarthrit.2019.08.007","article-title":"The preliminary validation of laser Doppler flowmetry in systemic sclerosis in accordance with the OMERACT filter","volume":"50","author":"Melsens","year":"2020","journal-title":"Sem Arthritis Rheum"},{"issue":"(Suppl 71)","key":"R17-20250526","first-page":"S103","article-title":"Use of infrared thermography as an endpoint in therapeutic trials of Raynaud's phenomenon and systemic sclerosis (Review)","volume":"30","author":"Pauling","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-1-4939-1526-2_13","article-title":"Noninvasive methods of assessing Raynaud's phenomenon","author":"Murray","year":"2015","journal-title":"Raynaud's phenomenon. A guide to pathogenesis and treatment"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/art.40457","article-title":"A multicentre study of the validity and reliability of responses to hand cold challenge as measured by laser speckle contrast imaging and thermography: outcome measures for systemic sclerosis-related Raynaud's phenomenon","volume":"70","author":"Wilkinson","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R20-20250526","doi-asserted-by":"crossref","DOI":"10.1080\/03009742.2021.1907926","article-title":"Temperature response to cold challenge and mobile phone thermography as outcome measures for systemic sclerosis-related Raynaud's phenomenon","author":"Herrick","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ultrasmedbio.2018.04.017","article-title":"Photoacoustic oxygenation quantification in patients with Raynaud's: first-in-human results","volume":"44","author":"Eisenbrey","year":"2018","journal-title":"Ultrasound Med Biol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13075-020-02400-y","article-title":"Photoacoustic and high-frequency ultrasound imaging of systemic sclerosis patients","volume":"23","author":"Daoudi","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"16444","DOI":"10.1038\/s41598-020-73319-2","article-title":"Three-dimensional optoacoustic imaging of nailfold capillaries in systemic sclerosis and its potential for disease differentiation using deep learning","volume":"10","author":"Nitkunanantharajah","year":"2020","journal-title":"Sci Rep"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13075-019-1822-1","article-title":"Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher\/European Scleroderma Trials and Research group (EUSTAR) survey","volume":"21","author":"Blagojevic","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/2397198318764796","article-title":"Reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: a challenge for clinical trial design","volume":"3","author":"Hughes","year":"2018","journal-title":"J Scleroderma Relat Disord"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5301\/jsrd.5000236","article-title":"Defining skin ulcers in systemic sclerosis: systematic literature review and proposed World Scleroderma Foundation (WSF) Definition","volume":"2","author":"Suliman","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/acr.24127","article-title":"Multicenter qualitative study exploring the patient experience of digital ulcers in systemic sclerosis","volume":"72","author":"Hughes","year":"2020","journal-title":"Arthritis Care Res"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"e037568","DOI":"10.1136\/bmjopen-2020-037568","article-title":"What narrative devices do people with systemic sclerosis use to describe the experience of pain from digital ulcers: a multicentre focus group study at UK scleroderma centres","volume":"10","author":"Jones","year":"2020","journal-title":"BMJ Open"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13075-019-2087-4","article-title":"Psychometric validation of the Hand Disability in Systemic Sclerosis-Digital Ulcers (HDISS-DU) patient-reported outcome instrument","volume":"22","author":"Mouthon","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3899\/jrheum.171486","article-title":"Preliminary validation of the Digital Ulcer Clinical Assessment Score in systemic sclerosis","volume":"46","author":"Bruni","year":"2019","journal-title":"J Rheumatol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/acr.23300","article-title":"Quantifying digital ulcers in systemic sclerosis: reliability of computer-assisted planimetry in measuring lesion size","volume":"70","author":"Simpson","year":"2018","journal-title":"Arthritis Care Res"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/annrheumdis-2017-212829","article-title":"Tracking digital ulcers in systemic sclerosis: a feasibility study assessing lesion area in patient-recorded smartphone photographs","volume":"77","author":"Dinsdale","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 106)","key":"R33-20250526","first-page":"S218","article-title":"A pilot study using high-frequency ultrasound to measure digital ulcers: a possible outcome measure in systemic sclerosis clinical trials?","volume":"35","author":"Hughes","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s10067-018-3986-5","article-title":"Ultrasound characterization of cutaneous ulcers in systemic sclerosis","volume":"37","author":"Suliman","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10067-019-04662-7","article-title":"Is there a role for laser speckle contrast analysis (LASCA) in predicting the outcome of digital ulcers in patients with systemic sclerosis?","volume":"39","author":"Barsotti","year":"2020","journal-title":"Clinical Rheumatol"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1093\/rheumatology\/keaa280","article-title":"Systemic sclerosis-related digital ulcers: a pilot study of cutaneous oxygenation and perfusion","volume":"59","author":"Marjanovic","year":"2020","journal-title":"Rheumatology"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13075-020-2140-3","article-title":"Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort","volume":"22","author":"Panopoulos","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/S2665-9913(19)30079-7","article-title":"Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials","volume":"1","author":"Khouri","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/rheumatology\/kev201","article-title":"Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis","volume":"54","author":"Hughes","year":"2015","journal-title":"Rheumatology"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/1759720X17740074","article-title":"Evidence based management of Raynaud's phenomenon","volume":"9","author":"Herrick","year":"2017","journal-title":"Ther Adv Musculoskel Dis"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40674-018-0102-6","article-title":"Pharmacotherapy options in the management of Raynaud's phenomenon","volume":"4","author":"Hinze","year":"2018","journal-title":"Curr Treat Opt Rheumatol"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/2397198318823951","article-title":"Management of Raynaud's phenomenon in systemic sclerosis: a practical approach","volume":"4","author":"Fernandez-Codina","year":"2019","journal-title":"J Scleroderma Relat Disord"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10238-019-00553-y","article-title":"Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study","volume":"19","author":"Negrini","year":"2019","journal-title":"Clin Exp Med"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3899\/jrheum.181173","article-title":"Worldwide expert agreement on updated recommendations for the treatment of systemic sclerosis","volume":"47","author":"de Vries-Bouwstra","year":"2020","journal-title":"J Rheumatol"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.40560","article-title":"Treatment algorithms for systemic sclerosis according to experts","volume":"70","author":"Fernandez-Codina","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"694","DOI":"10.7326\/M18-0517","article-title":"On-demand sildenafil as a treatment for Raynaud phenomenon: a series of n-of-1 trials","volume":"169","author":"Roustit","year":"2018","journal-title":"Ann Int Med"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.3390\/ijms21093161","article-title":"Sildenafil reduces expression and release of IL-6 and IL-8 induced by reactive oxygen species in systemic sclerosis fibroblasts","volume":"21","author":"Di Luigi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/jdv.15180","article-title":"The clinical effects of l-arginine and asymmetric dimethylarginine: implications for treatment in secondary Raynaud's phenomenon","volume":"33","author":"Curtiss","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5301\/jsrd.5000255","article-title":"Use of intravenous epoprostenol as a treatment for the digital vasculopathy associated with the scleroderma spectrum of diseases","volume":"2","author":"Law","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/03009742.2020.1845395","article-title":"Prostanoids in scleroderma microangiopathy: clinical and pharmacoeconomic comparison between two intravenous regimens","volume":"50","author":"Barsotti","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.semarthrit.2018.03.019","article-title":"Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: systematic literature review and expert consensus","volume":"48","author":"Ingegnoli","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"(Suppl 106)","key":"R53-20250526","first-page":"173","article-title":"A novel iloprost administration method with portable syringe pump for the treatment of acral ulcers and Raynaud's phenomenon in systemic sclerosis patients. A pilot study (ILOPORTA)","volume":"35","author":"Fraticelli","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"R54-20250526","first-page":"237","article-title":"Iloprost infusion through elastomeric pump for the outpatient treatment of severe Raynaud's phenomenon and digital ulcers: a single centre experience","volume":"43","author":"Duarte","year":"2018","journal-title":"Acta Reumatol Port"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/art.41536","article-title":"Dissecting the cellular mechanism of prostacyclin analog iloprost in reversing vascular dysfunction in scleroderma","volume":"73","author":"Tsou","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/01.CIR.3.5.681","article-title":"The effect of local application of glyceryl trinitrate (nitroglycerine) on Raynaud's disease and Raynaud's phenomenon: studies on blood flow and clinical manifestations","volume":"3","author":"Kleckner","year":"1951","journal-title":"Circulation"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaad.2018.01.043","article-title":"A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud's phenomenon","volume":"78","author":"Curtiss","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s00296-018-4119-9","article-title":"Use of nitroglycerin ointment to treat primary and secondary Raynaud's phenomenon: a systematic literature review","volume":"38","author":"Qui","year":"2018","journal-title":"Rheum Int"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaad.2017.08.018","article-title":"Nifedipine cream versus sildenafil cream for patients with secondary Raynaud phenomenon: a randomized, double-blind, controlled pilot study","volume":"78","author":"Wortsman","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ctim.2017.10.012","article-title":"Effect of topical rosemary essential oil on Raynaud phenomenon in systemic sclerosis","volume":"40","author":"von Schoen-Angerer","year":"2018","journal-title":"Complement Ther Med"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/10837450.2019.1578371","article-title":"Evaluation of topical econazole nitrate formulations with potential for treating Raynaud's phenomenon","volume":"24","author":"Bahl","year":"2019","journal-title":"Pharmaceut Dev Technol"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3390\/pharmaceutics11110594","article-title":"Development of a UV-stabilized topical formulation of nifedipine for the treatment of Raynaud phenomenon and chilblains","volume":"11","author":"Wasan","year":"2019","journal-title":"Pharmaceutics"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s10067-020-04966-z","article-title":"Possible benefit of tadalafil cream for the treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis","volume":"39","author":"Fernandez-Codina","year":"2020","journal-title":"Clin Rheumatol"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"814","DOI":"10.2533\/chimia.2020.814","article-title":"TOP-N53: a clinical drug candidate for the treatment of nonhealing wounds","volume":"74","author":"Naef","year":"2020","journal-title":"Chimia"},{"key":"R65-20250526","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/1358863X20953901","article-title":"Laser Doppler imaging evaluation of nitroglycerin patch application in systemic sclerosis patients","volume":"25","author":"Pintea Bentea","year":"2020","journal-title":"Vasc Med"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"119229","DOI":"10.1016\/j.ijpharm.2020.119229","article-title":"Ultrasound-mediated topical delivery of econazole nitrate with potential for treating Raynaud's phenomenon","volume":"580","author":"Daftardar","year":"2020","journal-title":"Int J Pharm"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/PRS.0000000000006908","article-title":"Nonaesthetic applications for botulinum toxin in plastic surgery","volume":"146","author":"Freeman","year":"2020","journal-title":"Plast Reconstr Surg"},{"issue":"(Suppl 125)","key":"R68-20250526","first-page":"S154","article-title":"Evaluation of botulinum toxin A injections for the treatment of refractory chronic digital ulcers in patients with systemic sclerosis","volume":"38","author":"Lautenbach","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/toxins13020120","article-title":"Therapeutic use of botulinum neurotoxins in dermatology: systematic review","volume":"13","author":"Martina","year":"2021","journal-title":"Toxins"},{"key":"R70-20250526","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jhsa.2020.07.009","article-title":"Botulinum toxin for the treatment of intractable Raynaud phenomenon","volume":"46","author":"Gallegos","year":"2021","journal-title":"J Hand Surg Am"},{"key":"R71-20250526","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/art.40123","article-title":"The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud's phenomenon: a randomized, double-blind, placebo-controlled clinical trial","volume":"69","author":"Bello","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R72-20250526","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s10067-019-04762-4","article-title":"Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series","volume":"38","author":"Dhaliwal","year":"2019","journal-title":"Clin Rheumatol"},{"key":"R73-20250526","doi-asserted-by":"crossref","first-page":"e14182","DOI":"10.1111\/dth.14182","article-title":"Botulinum toxin type A in the treatment of Raynaud's phenomenon","volume":"33","author":"Habib","year":"2020","journal-title":"Dermatol Therapy"},{"key":"R74-20250526","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00296-020-04606-4","article-title":"Targeted high concentration botulinum toxin A injections in patients with Raynaud's phenomenon: a retrospective single-centre experience","volume":"41","author":"Nagarajan","year":"2021","journal-title":"Rheumatol Int"},{"key":"R75-20250526","doi-asserted-by":"crossref","first-page":"513.e1","DOI":"10.1016\/j.jhsa.2020.11.005","article-title":"The effects of botulinum toxin A on pain in ischemic vasospasm","volume":"46","author":"Goldberg","year":"2021","journal-title":"J Hand Surg Am"},{"issue":"(Suppl 5)","key":"R76-20250526","doi-asserted-by":"crossref","first-page":"S386","DOI":"10.1097\/SAP.0000000000002303","article-title":"The use of ultrasound guidance for the treatment of Raynaud disease of the hand with botulinum toxin","volume":"84","author":"Lobb","year":"2020","journal-title":"Ann Plastic Surg"},{"key":"R77-20250526","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1152\/japplphysiol.00292.2019","article-title":"\u2018Beet\u2019 the cold: beetroot juice supplementation improves peripheral blood flow, endothelial function, and anti-inflammatory status in individuals with Raynaud's phenomenon","volume":"127","author":"Shepherd","year":"2019","journal-title":"J Applied Physiol"},{"key":"R78-20250526","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s10067-019-04921-7","article-title":"Exploring the feasibility of an exercise programme including aerobic and resistance training in people with limited cutaneous systemic sclerosis","volume":"39","author":"Mitropoulos","year":"2020","journal-title":"Clin Rheumatol"},{"key":"R79-20250526","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1177\/0269215520907652","article-title":"The complementary effects of galvanic current electrical stimulation associated with conservative treatment to increase vasodilation in patients with Raynaud's phenomenon: a randomized trial","volume":"34","author":"Tapia-Haro","year":"2020","journal-title":"Clin Rehab"},{"key":"R80-20250526","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/rheumatology\/kez386","article-title":"Treatment of resistant Raynaud's phenomenon with single-port thoracoscopic sympathicotomy: a minimally invasive endoscopic technique","volume":"59","author":"Van Room","year":"2020","journal-title":"Rheumatology"},{"key":"R81-20250526","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1111\/bcp.14322","article-title":"Drug repurposing in Raynaud's phenomenon through adverse event signature matching in the World Health Organization pharmacovigilance database","volume":"86","author":"Putkaradze","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"R82-20250526","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10067-019-04564-8","article-title":"Use of vasoactive\/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study","volume":"39","author":"Blagojevic","year":"2020","journal-title":"Clin Rheumatol"},{"key":"R83-20250526","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keab147","article-title":"A clinical comparison of an endothelin receptor antagonist and phosphodiesterase type 5 inhibitors for treating digital ulcers of systemic sclerosis","author":"Chang","year":"2021","journal-title":"Rheumatology"},{"key":"R84-20250526","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.mvr.2016.12.008","article-title":"Reduced perfusion in systemic sclerosis digital ulcers (both fingertip and extensor) can be increased by topical application of glyceryl trinitrate","volume":"111","author":"Hughes","year":"2017","journal-title":"Microvasc Res"},{"key":"R85-20250526","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/jcph.1574","article-title":"Treprotinil hydrogel iontophoresis in systemic sclerosis-related digital skin ulcers: a safety study","volume":"60","author":"Guigui","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"R86-20250526","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1007\/s00266-020-01848-2","article-title":"Autologous fat grafting for the oral and digital complications of systemic sclerosis: results of a prospective study","volume":"44","author":"Pignatti","year":"2020","journal-title":"Aesth Plast Surg"},{"key":"R87-20250526","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/09546634.2018.1484875","article-title":"A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis","volume":"30","author":"Hughes","year":"2019","journal-title":"J Dermatol Treat"},{"key":"R88-20250526","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fmed.2019.00208","article-title":"Rheopheresis for digital ulcers and Raynaud's phenomenon in systemic sclerosis refractory to conventional treatments","volume":"6","author":"Korsten","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"R89-20250526","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejim.2021.01.022","article-title":"Prediction and primary prevention of major vascular complications in systemic sclerosis","volume":"87","author":"Bruni","year":"2021","journal-title":"Eur J Int Med"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T22:00:43Z","timestamp":1748296843000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":89,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000826","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]}}}